MN-AYMIUM
6.6.2024 13:01:27 CEST | Business Wire | Press release
Aymium, the leading producer of renewable biocarbon products, announced today that it closed $210 Million of financing to construct a biocarbon production facility in Williams, California. The facility will support the first large-scale continuous use of advanced biocarbon to replace coal in power generation in the world. Use of the product from the Williams facility to replace coal will reduce greenhouse gas emissions by over 500,000 metric tons per year—equivalent to removing over 120,000 cars from the road annually. Construction of the facility is scheduled to be completed in 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606231738/en/
Aymium's reactor being delivered to the new biocarbon production facility in Williams, CA. The biocarbon will replace coal in power generation around the world and reduce greenhouse gas emissions by more than 500,000 metric tons per year, equivalent to removing 120,000 cars annually. (Photo: Business Wire)
“We are excited to have the support from such an experienced group of investors from Asia, North America and Europe,” said James Mennell, CEO of Aymium. “These groups share a profound commitment to decarbonization and have come together to advance this technology that will create a substantial reduction in greenhouse gas emissions for many years.”
The facility will be funded by a global group of investors dedicated to next-generation decarbonization technologies. Senior debt, in the form of green bonds, will be provided jointly by ECP ForeStar and Copenhagen Infrastructure Partners (CIP) through its Green Credit Fund. Subordinated debt will be provided by Japan Green Investment Corp. for Carbon Neutrality (“JICN”) and Aymium. Equity for the project will come from Hokuriku Electric Power Company, Nippon Steel Trading, and Aymium.
U.S. Ambassador to Japan Rahm Emanuel said: “A global threat like climate change demands a global solution. The only way to tackle a challenge of this magnitude is by thinking and collaborating across borders. With the United States and Japan cooperating on a multitude of areas related to energy and the environment, Aymium’s groundbreaking biocarbon production facility is the latest project to benefit from this flourishing relationship.”
Reiner Boehning, Managing Partner of ECP ForeStar said: “Aymium, together with its partners, has developed a proven production process that is an important building block to help decarbonize industrial processes, like steel making, and power generation. We are thrilled to be part of the investor group that finances the construction of Aymium’s next production facility in Williams, California.”
Jakob Groot, Partner at CIP and co-head of its Green Credit Fund, said: “We are proud to be part of this experienced lending consortium that is supporting Aymium in financing the construction of the Williams project and Hokuriku Electric in their continued decarbonization efforts. This financing represents an attractive opportunity for us and our investors to make yet another meaningful contribution to the green transition.”
Aymium produces the only commercially demonstrated carbon-negative product for replacing coal in power generation. Aymium’s renewable product is created through a non-combustion process that converts waste biomass to high purity biocarbon. The product is specifically engineered to immediately replace fossil coal without the need for any type of plant investment or process modification. The product has superior energy value, handling, and environmental attributes to coal. The process uses third-party certified sustainable waste biomass and is powered by self-generated renewable energy. Aymium’s process and product technologies are protected by more than 500 issued and pending patents. Aymium’s investors include Hokuriku Electric, Nippon Steel Trading, Rio Tinto and Steel Dynamics. Morgan Stanley served as debt arranger to Aymium in this transaction.
About Aymium
Aymium produces high-value biocarbon and biohydrogen products that can be used to immediately replace fossil fuels in the production of energy, metals, crops, and in the purification of water and air with no modifications to equipment or processes. Produced using sustainably sourced biomass – recovered and unusable wood – Aymium’s bioproducts are renewable, carbon-negative and they replace emission-heavy fossil fuels such as coal and coke. Aymium’s leading technology is backed by more than 500 issued or pending patents on a global basis. Aymium is headquartered in Minnesota, USA.
About Hokuriku Electric Power Company
Established in 1951, Hokuriku Electric Power Company is a comprehensive energy company that aims to contribute to the development of the Hokuriku region through the stable supply of affordable and high-quality energy. The company's vision for the future is to “develop together with Hokuriku and deliver new value nationwide and overseas,” and it is expanding its business beyond the existing electric power business while contributing to social issues such as addressing the global warming, sustainable development of the region, and the realization of a smart society.
About Copenhagen Infrastructure Partners
Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focus on investments in offshore and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity, storage, advanced bioenergy, and Power-to-X.
CIP manages 12 funds and has to date raised approximately EUR 28 billion for investments in energy and associated infrastructure from more than 160 international institutional investors. CIP has approximately 500 employees and 12 offices around the world. For more information, visit www.cip.com.
About Japan Green Investment Corp. for Carbon Neutrality
Japan Green Investment Corp. for Carbon Neutrality (“JICN”) is a fund established through public-private partnership of the Japanese Government and Japanese private institutions, headquartered in Tokyo, JAPAN. JICN provides financing in the form of preferred equity investment and mezzanine or subordinated loans for startups and projects that contribute to the carbon neutrality as well as virtuous cycle between the environment and the economy.
About Nippon Steel Trading
Nippon Steel Trading Corporation is the core trading company of NIPPON STEEL CORPORATION Group, and was established in October 2013 through the merger of Nippon Steel Trading Co., Ltd. and Sumikin Bussan Corporation. The company continues to grow as a multiple specialty trading company operating four integrated core businesses: Steel, Industrial Supply & Infrastructure, Textiles, and Foodstuffs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606231738/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom